Nadunolimab awarded US FDA Fast Track Designation for the treatment of patients with metastatic PDAC with high IL1RAP expression levels June 17, 2025
FDA authorizes Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers June 17, 2025
CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the 1L Treatment of Gastric/GEJ Cancer June 17, 2025
CHM CDH17 granted Fast Track for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) June 11, 2025
Tempest Receives Orphan Drug Designation from the EMA for Amezalpat for the Treatment of Patients with HCC June 10, 2025
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
NMPA Approves Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer June 3, 2025
Positive Results from Ph 3 TALENTACE Study of Tecentriq and Avastin for Unresectable HCC announced May 27, 2025
NMPA CDE grants Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC May 27, 2025
IDeate-Esophageal01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma May 21, 2025
Leap Therapeutics undergoes strategic restructuring to prioritize clinical development of sirexatamab in CRC resulting in an approximately 50% reduction in workforce May 21, 2025
Statistically Significant Topline Results from Global Ph 2 Trial of Elraglusib in 1L Treatment of Metastatic Pancreatic Cancer Announced May 13, 2025
Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Ph 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in 1L Metastatic Pancreatic Cancer Patients May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
Sandoz enters global collaboration license agreement with Henlius to commercialize ipilimumab in multiple indications May 6, 2025
Ph 2/3 trial of 2L+ KN026 + chemo in HER2-positive gastric/GEJ cancer met the primary endpoint of PFS at interim analysis May 6, 2025
Ph 1 study targeting GPC3 with 225Ac-GPC3 (BAY 3547926) in patients with advanced HCC initiated May 6, 2025
Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer May 6, 2025
CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer April 30, 2025
